QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.57−0.30 (-3.04%)
Close on Nov 18, 2026Market cap $656.27MP/E –Yield –
QuidelOrtho revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
QuidelOrtho's revenue for the twelve months ending Sep 27, 2026 was $2.59B, down 4.5% year over year. For fiscal 2025 it was $2.73B, down 1.9% from the year before. The highest annual figure on record is $3.27B in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $2.73B | -1.9% |
| FY2024 | Dec 29, 2024 | $2.78B | -7.2% |
| FY2023 | Dec 31, 2023 | $3.00B | -8.2% |
| FY2022 | Jan 1, 2023 | $3.27B | +92.3% |
| FY2021 | Jan 2, 2022 | $1.70B | +2.2% |
| FY2020 | Jan 3, 2021 | $1.66B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $618.90M | -11.6% |
| Q2 FY2026 | Jun 28, 2026 | $630.90M | +2.8% |
| Q1 FY2026 | Mar 29, 2026 | $619.80M | -10.5% |
| Q4 FY2025 | Dec 28, 2025 | $723.60M | +2.2% |
| Q3 FY2025 | Sep 28, 2025 | $699.90M | -3.7% |
| Q2 FY2025 | Jun 29, 2025 | $613.90M | -3.6% |
| Q1 FY2025 | Mar 30, 2025 | $692.80M | -2.6% |
| Q4 FY2024 | Dec 29, 2024 | $707.80M | -4.7% |
| Q3 FY2024 | Sep 29, 2024 | $727.10M | -2.3% |
| Q2 FY2024 | Jun 30, 2024 | $637.00M | -4.2% |
| Q1 FY2024 | Mar 31, 2024 | $711.00M | -16.0% |
| Q4 FY2023 | Dec 31, 2023 | $742.60M | -14.3% |
| Q3 FY2023 | Oct 1, 2023 | $744.00M | -5.1% |
| Q2 FY2023 | Jul 2, 2023 | $665.10M | +8.4% |
| Q1 FY2023 | Apr 2, 2023 | $846.10M | -15.6% |
| Q4 FY2022 | Jan 1, 2023 | $866.50M | +36.0% |
| Q3 FY2022 | Oct 2, 2022 | $783.80M | +53.7% |
| Q2 FY2022 | Jul 3, 2022 | $613.40M | +247.3% |
| Q1 FY2022 | Apr 3, 2022 | $1.00B | – |
| Q4 FY2021 | Jan 2, 2022 | $636.90M | – |
| Q3 FY2021 | Oct 3, 2021 | $509.80M | – |
| Q2 FY2021 | Jul 4, 2021 | $176.60M | – |
See a number that looks wrong?